News
CLLS
2.690
-4.95%
-0.140
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes...
GlobeNewswire · 1d ago
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced...
GlobeNewswire · 3d ago
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France. At the meeting, during which 67.23% of voting rights were...
GlobeNewswire · 3d ago
Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?
Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 4d ago
Cellectis Files for Up to $200 Million Mixed-Securities Shelf
MT Newswires · 5d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 06/22 12:06
Top Premarket Decliners
MT Newswires · 06/22 08:22
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights05/31/2...
GlobeNewswire · 06/08 20:30
European ADRs Move Lower in Wednesday Trading
MT Newswires · 06/01 11:12
--Goldman Sachs Adjusts Cellectis' Price Target to $2 from $3, Keeps Sell Rating
MT Newswires · 05/24 11:44
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold...
GlobeNewswire · 05/23 20:35
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
Benzinga · 05/19 16:31
Baird Upgrades Cellectis to Outperform From Neutral
MT Newswires · 05/18 06:10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 05/17 12:09
BRIEF-Cellectis To Present Immune-Evasive Universal CAR T-Cell Data
reuters.com · 05/16 12:17
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will prese...
GlobeNewswire · 05/16 12:15
--Barclays Lowers Cellectis S.A's Price Target to $7 From $9, Overweight Rating Maintained
MT Newswires · 05/13 10:41
Cellectis Q1 EPS $(0.64) Down From $(0.26) YoY, Sales $3.83M Down From $27.97M YoY
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share. This is a 146.15 percent decrease over losses of $(0.26) per share from the same period last year. The company reported $3.83 million in sales this
Benzinga · 05/12 21:13
BRIEF-Cellectis Provides Reports Results For First Quarter 2022
reuters.com · 05/12 20:50
Cellectis Non-GAAP EPS of -$0.64 beats by $0.02, revenue of $3.83M misses by $14.68M
Cellectis press release (NASDAQ:CLLS): Q1 Non-GAAP EPS of -$0.64 beats by $0.02. Revenue of $3.83M (-86.3% Y/Y) misses by $14.68M. "Based on our current operating plan, our cash position of
Seekingalpha · 05/12 20:36
More
Webull provides a variety of real-time CLLS stock news. You can receive the latest news about Cellectis through multiple platforms. This information may help you make smarter investment decisions.
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.